Balipodect

Balipodect

Clinical data
Other names	TAK-063; TAK063
Drug class	Phosphodiesterase inhibitor; PDE10A inhibitor; Antipsychotic
Identifiers
IUPAC name 1-(2-fluoro-4-pyrazol-1-ylphenyl)-5-methoxy-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
CAS Number	1238697-26-1
PubChem CID	46848915
DrugBank	DB14774
ChemSpider	35035198
UNII	6650W303H0
KEGG	D11245
ChEMBL	ChEMBL3989972
Chemical and physical data
Formula	C23H17FN6O2
Molar mass	428.427 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F
InChI InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3 Key:KVHRYLNQDWXAGI-UHFFFAOYSA-N

Balipodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia.¹²³

It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.⁴

The drug reached phase 2 clinical trials for this indication but its development was discontinued.¹² It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.⁵⁶⁷